Lomitapide Emerging Drug Insight and Market Forecast - 2032

Lomitapide Emerging Drug Insight and Market Forecast − 2032

“Lomitapide Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about lomitapide for Severe Hypertriglyceridemia (SHTG) in the six major markets. A detailed picture of the lomitapide for severe hypertriglyceridemia in the 6MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this report along with a detailed description of the lomitapide for severe hypertriglyceridemia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the lomitapide market forecast analysis for severe hypertriglyceridemia in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in severe hypertriglyceridemia.

Drug Summary

Lomitapide is a small molecule administered orally, which is a selective inhibitor of microsomal triglyceride transfer protein (MTP), a protein necessary for the proper assembly and secretion of cholesterol containing molecules in the liver and the intestines, is currently in Phase II of its clinical development in the pipeline of Amryt Pharma for the indication Familial Chylomicronemia Syndrome. Inhibition of MTP reduces the levels of cholesterol containing molecules including cholesterol, LDL-C and triglycerides in the blood.

In December 2012, the US FDA granted authorisation for lomitapide under the trade name ‘JUXTAPID’ as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-highdensity lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Scope of the Report

The report provides insights into:

A comprehensive product overview including the lomitapide description, mechanism of action, dosage and administration, research and development activities in severe hypertriglyceridemia.

Elaborated details on lomitapide regulatory milestones and other development activities have been provided in this report.

The report also highlights the lomitapide research and development activities in severe hypertriglyceridemia across the United States and Europe.

The report also covers the patents information with expiry timeline around lomitapide.

The report contains forecasted sales of lomitapide for severe hypertriglyceridemia till 2032.

Comprehensive coverage of the late-stage emerging therapies for severe hypertriglyceridemia.

The report also features the SWOT analysis with analyst views for lomitapide in severe hypertriglyceridemia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lomitapide Analytical Perspective by DelveInsight

In-depth Lomitapide Market Assessment

This report provides a detailed market assessment of lomitapide for severe hypertriglyceridemia in the six major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.

Lomitapide Clinical Assessment

The report provides the clinical trials information of lomitapide for severe hypertriglyceridemia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for severe hypertriglyceridemia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence lomitapide dominance.

Other emerging products for severe hypertriglyceridemia are expected to give tough market competition to lomitapide and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of lomitapide in severe hypertriglyceridemia.

Our in-depth analysis of the forecasted sales data of lomitapide from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the lomitapide in severe hypertriglyceridemia.

Key Questions

What is the product type, route of administration and mechanism of action of lomitapide?

What is the clinical trial status of the study related to lomitapide in severe hypertriglyceridemia and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the lomitapide development?

What are the key designations that have been granted to lomitapide for severe hypertriglyceridemia?

What is the forecasted market scenario of lomitapide for severe hypertriglyceridemia?

What are the forecasted sales of lomitapide in the six major countries, including the United States, Germany, France, Italy, Spain, and the United Kingdom?

What are the other emerging products available and how are these giving competition to lomitapide for severe hypertriglyceridemia?

Which are the late-stage emerging therapies under development for the treatment of severe hypertriglyceridemia?